Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pin Zhang

Showing results (271-280 of 373) with videos related to

Pageof 38
Sort By:
Anti-Cancer Drugs|October 14, 2020
TNM stage at diagnosis is more predictive of prognosis than pathological complete response in young breast cancer treated with neoadjuvant chemotherapyJingjing Wang, Qing Li, Pin Zhang, et al.
International Journal of Cancer|April 11, 2022
Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysisMeng Xiu, Pin Zhang, Xiang Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|September 23, 2020
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancerQing Li, Jiani Wang, Yuxin Mu, et al.
Chinese Journal of Cancer|February 1, 2018
Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapyMeiying Li, Fei Ma, Jiayu Wang, et al.
Frontiers in Oncology|June 2, 2023
Association between ultrasound BI-RADS signs and molecular typing of invasive breast cancerQiao-Hong Pan, Zheng-Pin Zhang, Liu-Yi Yan, et al.
Nature Communications|February 6, 2026
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trialPin Zhang, Tao Sun, Ying Wang, et al.
Combinatorial Chemistry & High Throughput Screening|February 21, 2017
In Silico Prediction of Chemical Toxicity Profile Using Local Lazy LearningJing Lu, Pin Zhang, Xiao-Wen Zou, et al.
International Journal of Surgery (London, England)|January 24, 2024
The current status and challenges of perioperative management of patients with a BMI of greater than or equal to 50 kg/m 2 undergoing bariatric surgery in China: a multicenter cross-sectional studyNingli Yang, Hongxia Hua, Shaozhuang Liu, et al.
Patient Preference and Adherence|June 23, 2026
Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort StudyFang Zhao, Yuqiu Li, Yanjun Zhou, et al.
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban|April 18, 2013
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancerYi Yin, Pin Zhang, Bing-He Xu, et al.
Pageof 38

Showing results (271-280 of 373) with videos related to

Sort By:
Pageof 38
Anti-Cancer Drugs|October 14, 2020
TNM stage at diagnosis is more predictive of prognosis than pathological complete response in young breast cancer treated with neoadjuvant chemotherapyJingjing Wang, Qing Li, Pin Zhang, et al.
International Journal of Cancer|April 11, 2022
Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysisMeng Xiu, Pin Zhang, Xiang Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|September 23, 2020
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancerQing Li, Jiani Wang, Yuxin Mu, et al.
Chinese Journal of Cancer|February 1, 2018
Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapyMeiying Li, Fei Ma, Jiayu Wang, et al.
Frontiers in Oncology|June 2, 2023
Association between ultrasound BI-RADS signs and molecular typing of invasive breast cancerQiao-Hong Pan, Zheng-Pin Zhang, Liu-Yi Yan, et al.
Nature Communications|February 6, 2026
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trialPin Zhang, Tao Sun, Ying Wang, et al.
Combinatorial Chemistry & High Throughput Screening|February 21, 2017
In Silico Prediction of Chemical Toxicity Profile Using Local Lazy LearningJing Lu, Pin Zhang, Xiao-Wen Zou, et al.
International Journal of Surgery (London, England)|January 24, 2024
The current status and challenges of perioperative management of patients with a BMI of greater than or equal to 50 kg/m 2 undergoing bariatric surgery in China: a multicenter cross-sectional studyNingli Yang, Hongxia Hua, Shaozhuang Liu, et al.
Patient Preference and Adherence|June 23, 2026
Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort StudyFang Zhao, Yuqiu Li, Yanjun Zhou, et al.
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban|April 18, 2013
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancerYi Yin, Pin Zhang, Bing-He Xu, et al.
Pageof 38